Cargando…
Molecular and Immune Biomarkers for Cutaneous Melanoma: Current Status and Future Prospects
SIMPLE SUMMARY: The prognosis and treatment of metastatic melanoma have changed substantially since the advent of target therapy and immune checkpoint inhibitors. Thus, strategies must be developed to identify responder patients, reduce toxicities, and investigate target and immune based therapy ide...
Autores principales: | Pilla, Lorenzo, Alberti, Andrea, Di Mauro, Pierluigi, Gemelli, Maria, Cogliati, Viola, Cazzaniga, Marina Elena, Bidoli, Paolo, Maccalli, Cristina |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7699774/ https://www.ncbi.nlm.nih.gov/pubmed/33233603 http://dx.doi.org/10.3390/cancers12113456 |
Ejemplares similares
-
Editorial: Molecular Genetics of Cutaneous Melanoma: Current Status and Future Direction
por: Pellegrini, Cristina, et al.
Publicado: (2021) -
Immune Profiling of Cancer Patients Treated with Immunotherapy: Advances and Challenges
por: Pilla, Lorenzo, et al.
Publicado: (2018) -
Ex vivo enrichment of circulating anti-tumor T cells from both cutaneous and ocular melanoma patients: clinical implications for adoptive cell transfer therapy
por: Mazzarella, Tonia, et al.
Publicado: (2011) -
Editorial: Molecular genetics of cutaneous melanoma: current status and future direction-volume II
por: Garcia-Casado, Zaida, et al.
Publicado: (2023) -
Treatment of cutaneous melanoma: current approaches and future prospects
por: Algazi, Alain P, et al.
Publicado: (2010)